Design Therapeutics, Inc. DSGN EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Design Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: Design Therapeutics, Inc.’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about Design Therapeutics, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Design Therapeutics, Inc.'s EPS (diluted)?
- Design Therapeutics, Inc. (DSGN) reported EPS (diluted) of -$0.29 in Q1 2026.
- How has Design Therapeutics, Inc.'s EPS (diluted) changed year-over-year?
- Design Therapeutics, Inc.'s EPS (diluted) increased by 6.5% year-over-year, from -$0.31 to -$0.29.
- What is the long-term trend for Design Therapeutics, Inc.'s EPS (diluted)?
- Over 4 years (2021 to 2025), Design Therapeutics, Inc.'s EPS (diluted) has grown at a 9.1% compound annual growth rate (CAGR), from -$0.86 to -$1.22.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.